ABSTRACT Blood‐based biomarkers are central to diagnostics, yet current approaches depend on invasive sampling and centralized laboratory infrastructure. At the same time, women's reproductive health remains severely under‐monitored: most clinically relevant biomarkers are rarely measured outside fertility clinics, leaving millions without accessible, continuous insight into their reproductive lifespan. Anti‐Müllerian hormone (AMH), a key indicator of ovarian reserve and overall reproductive function, still requires venous blood collection and specialized analysis, creating a major barrier to early detection, routine monitoring, and population‐level screening. Here, we present a lateral flow assay (LFA) enabling direct AMH detection in unprocessed menstrual blood. The assay uses covalently conjugated 150 nm gold nanoshells to achieve sensitive colorimetric detection within the clinically relevant 0–10 ng/mL range. Results can be visually interpreted by naked‐eye detection or quantified via a smartphone‐based machine‐learning algorithm for semi‐quantitative assessment. The LFA performance correlates strongly with clinical chemistry lab‐based analyses and can be seamlessly integrated into point‐of‐care formats, including wearable menstruation pads as well as simple dipstick tests. This technology demonstrates the feasibility of a non‐invasive and affordable approach for decentralized ovarian health assessment.
Dosnon et al. (Fri,) studied this question.